Analysts are skeptical of the massive 30-40% gap in 2026 sales projections between Eli Lilly (+25%) and Novo Nordisk (-5% to -13%). Given that the two companies are "joined at the hip" in the GLP-1 market, such a dramatic divergence in financial trajectory is considered highly improbable by some observers.

The imbalance between rising drug development costs and financially strained public health systems is unsustainable. Novo Nordisk's CEO believes this will inevitably lead to a global trend of increased patient cost-sharing through cash channels and high co-pays, moving beyond traditional insurance models.

For out-of-pocket drugs like oral Wegovy, Novo Nordisk leverages telehealth platforms for distribution. This GTM strategy achieves rapid patient uptake, contrasting with slower, traditional models that rely on educating and detailing primary care physicians, reaching 300,000 UK patients in weeks.

The emergence of low-cost, compounded versions of GLP-1 drugs from telehealth companies like Hims is creating significant pricing pressure on market leaders Novo Nordisk and Eli Lilly. This dynamic has pushed the pharma giants toward direct-to-consumer models with lower prices to compete.

Pharma companies now partner with telehealth providers to offer coupons that reduce the cost of the physician consultation itself. This marketing tactic incentivizes patients to seek a prescription for a specific drug, raising questions about overprescribing and conflicts of interest.

Despite generating enormous amounts of data from hubs, specialty pharmacies, and copay programs, the data remains siloed. This fragmentation prevents a holistic patient view, leading to poor decision-making, patient non-adherence, and significant avoidable healthcare costs.

The competitive advantage in pharma isn't the sophistication of an AI algorithm, which is often a commodity built on third-party models. The true differentiator is the quality, relevance, and end-to-end consistency of the proprietary data used to train and validate these models. Poor data invalidates even the best analytics.

Novo Nordisk and Eli Lilly, after criticizing telehealth companies for unsafe compounded drugs, now partner with and promote platforms like LifeMD, which are accused of questionable prescribing practices. This suggests a potential hypocrisy driven by the need for broad market access for their branded GLP-1s.

Companies like "Prescriberee" operate with a business model targeting life sciences firms as clients. Their goal is not holistic care but efficiently converting interested patients into prescriptions, with one executive citing a 90% conversion rate for eligible patients.